Liminatus Pharma, Inc.

Liminatus Pharma is a biopharmaceutical company developing cancer immunotherapies, with its lead asset being IBA101, a humanized monoclonal antibody that blocks the CD47 "do not eat me" signal to restore immune cells' ability to destroy cancer cells. Unlike earlier CD47 inhibitors, IBA101 preferentially binds immune cells while avoiding unwanted binding to red blood cells and platelets, reducing adverse effects while showing synergistic potential when combined with other checkpoint inhibitors such as PD-1/PD-L1 blockers. The company targets advanced solid cancers, particularly non-small cell lung cancer, and plans to pursue both monotherapy and combination trials, with manufacturing handled by third-party contractors and its intellectual property licensed from InnoBation and protected by patent applications and regulatory exclusivity provisions.